Population
Patients with human heart failure
Design
Review
Authors
Loading...
May support exploration of PDE3/CaMKII targets in heart failure; leaves open whether inhibition improves outcomes.
Understanding downstream beta-adrenergic signaling pathways such as PDE3, phospholamban, and CaMKII may provide novel therapeutic targets for heart failure.
Carmen C. Sucharov (2006) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: